A Phase 3 interventional study of Omeprazole in GERD, sponsored by AstraZeneca. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing omeprazole in Gastroesophageal Reflux — 3 open to participants now, 3 under way, none of them phase 3. Omeprazole · Gastroesophageal Reflux.
Among the 21 studies testing omeprazole in Gastroesophageal Reflux, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 1998, is the only one in phase 3, and was the 1st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →3 of the 21 studies testing omeprazole in Gastroesophageal Reflux are open now, in 3 countries. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 1 mo–1 yrs
Nationwide Children's Hospital · Sites in United States
Ages 1 days–8 mo
Federal State Budgetary Scientific Institution · Sites in Russia
Ages 50–65
By country, each count listing its studies:
Omeprazole: first FDA approval 1989 (PRILOSEC). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 54 across the 20 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
89 studies in Gastroesophageal Reflux by AstraZeneca: none open now, none under way, none of them phase 3. Of 89 finished, 15 (17%) have results posted.
Among the 89 studies in Gastroesophageal Reflux by AstraZeneca, this one is the 27th largest by enrollment of the 52 interventional ones that give a count, is the only one that started in 1998, is one of 13 in phase 3, and was the 13th registered.
AstraZeneca’s Gastroesophageal Reflux studies by the year they started, since 1998.
2 of the studies testing omeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07850960Federal State Budgetary Scientific InstitutionEffect of Omeprazole on Gut Microbiota in Adults With Obesity and GERD | 2026-12-25 |
| NCT06255886Odense University HospitalTreatment of Gastroesophageal Reflux Disease in Infants | 2026-12-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing omeprazole in Gastroesophageal Reflux, from their registry updates:
Among AstraZeneca’s 89 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Determine the safety of omeprazole during long term treatment
To investigate the long term control of reflux symptoms, healing of esophagitis and persistence of post fundoplication symptoms during long term treatment of omeprazole
The record gives a start of Jan 1998, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omeprazole